# Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

> **NCT06065371** · PHASE1 · RECRUITING · sponsor: **Henry Ford Health System** · enrollment: 20 (estimated)

## Conditions studied

- Gastrointestinal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Sacituzumab govetican

## Key facts

- **NCT ID:** NCT06065371
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-20
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06065371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06065371, "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06065371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*